ArticleFrontiers in oncology2020
Dual Primary Cancer Patients With Lung Cancer as a Second Primary Malignancy: A Population-Based Study.
Article in Frontiers in oncology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 37 citations in OpenAlex.
- Complete Imaging Resolution of Ductal Carcinoma In Situ During Osimertinib Therapy for Synchronous EGFR Exon 19-Mutant Non-Small Cell Lung Cancer: A Case Report.International journal of molecular sciences · 2026Article
- Dual primary cancers of skin cancer and lung cancer: a case report.Journal of cardiothoracic surgery · 2026Article
- Genetic Association of Primary Lung Cancer With Urological Cancers: A Bidirectional Mendelian Randomization Study and SEER Database Validation.Cancer medicine · 2025Article
- Observational
- Pulmonary metastasis risk and overall survival score in choriocarcinoma: a novel nomogram-based risk assessment system.Translational cancer research · 2025Article
- Nomograms based on clinical factors to predict abnormal metabolism of psychotropic drugs.Biomedical reports · 2025Article
- Survival Analysis of Secondary Primary Lung Cancer After Breast Cancer Patients: Insights From a Retrospective Single-Center Study of Clinical Outcomes and Prognostic Indicators.Thoracic cancer · 2025Article
- Double the trouble: pulmonary enteric adenocarcinoma with synchronous contralateral pulmonary adenocarcinoma.Oxford medical case reports · 2025Article
- Does chemotherapy improve survival outcomes in breast cancer survivors with secondary primary stage I non-small cell lung cancer? A real-world analysis using machine learning models.Frontiers in oncology · 2025Article
- Risk factors, prognostic factors, and nomograms for distant metastasis in patients with diagnosed duodenal cancer: A population-based study.World journal of gastrointestinal oncology · 2024Article
- Effect of a prior thyroid cancer on the survival of lung cancer patients: a retrospective study based on SEER database.Endocrine · 2024Article
- Carcinoma lung with cutaneous metastasis: experience from an Indian institute.Reports of practical oncology and radiotherapy : journal of Greatpoland Cancer Center in Poznan and Polish Society of Radiation Oncology · 2024Article
- [Risk Factors and Pathogenic Mechanism for Secondary Primary Lung Cancer in Breast Cancer Patients: A Review].Zhongguo fei ai za zhi = Chinese journal of lung cancer · 2022Review
- Pathological and clinical features of multiple cancers and lung adenocarcinoma: a multicentre study.Interactive cardiovascular and thoracic surgery · 2022Article
- Second Primary Lung Adenocarcinoma After Intensity-Modulated Radiotherapy for Nasopharyngeal Carcinoma.Frontiers in oncology · 2022Article
- Analysis of prognosis and treatment decisions for patients with second primary lung cancer following esophageal cancer.Frontiers in oncology · 2022Article
- Development and Validation of a Nomogram for Predicting Overall Survival in Patients with Second Primary Small Cell Lung Cancer After Non-Small Cell Lung Cancer: A SEER-Based Study.International journal of general medicine · 2022Article
- Smart Nanotherapeutics and Lung Cancer.Pharmaceutics · 2021Review
- Article
- Risk Factors, Prognostic Factors, and Nomograms for Distant Metastasis in Patients With Newly Diagnosed Osteosarcoma: A Population-Based Study.Frontiers in endocrinology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundResearch on patients with lung cancer as a second primary malignancy (LCSPM) remains limited. This study aims to determine the clinical characteristics, prognosis, and temporal relationship of other cancers to lung cancer in these patients.
methodsThis study retrospectively analyzed 3465 patients with dual primary cancers from the 5253 patients with LCSPM retrieved from the Surveillance, Epidemiology and End Results (SEER) database from 2010 to 2015.
results2285 eligible patients were further analyzed in this study cohort with 59.3% of 1-year OS, 34.7% of 3-year OS, and 25.2% of 5-year OS. The most common first primary cancer (FPC) in dual primary cancer patients with LCSPM was prostate cancer, followed by female breast cancer and urinary bladder cancer. In the entire study population, the median interval between the two primary malignancies was 21 months (range: 3.5-52 months). Age, sex, FPC location, surgery, stage, and histology of lung cancer were regarded as independent prognostic factors for these patients. The prognosis of patients with urinary bladder cancer as FPC was the worst in the univariate (
conclusionsCancer patients still have the risk of developing a new primary lung cancer. Close, lifelong follow-up is recommended for all these patients. Early detection for surgical treatment will significantly improve the prognosis of dual primary cancer patients with LCSPM. The nomogram developed to predict 1-, 3-, and 5-year OS rates has relatively good performance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.